MiR-424/503-Mediated rictor upregulation promotes tumor progression

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Oneyama, Chitose ^a   Kito, Yoriko ^a   Asai, Rei ^a   Ikeda, Jun Ichiro ^b   Yoshida, Takuya ^c   Okuzaki, Daisuke ^a   Kokuda, Rie ^a   Kakumoto, Kyoko ^a   Takayama, Ken Ichi ^d,e   Inoue, Satoshi ^d,e   Morii, Eiichi ^b   Okada, Masato ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICRORNA; MIR 424; MIR 503; PROTEIN KINASE P60; RICTOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; MIRN424 MICRORNA, HUMAN; MIRN503 MICRORNA, HUMAN; MULTIPROTEIN COMPLEX; RICTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL INVASION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROSTATE CANCER; TUMOR GROWTH; UPREGULATION; COLON TUMOR; CYTOSKELETON; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOSKELETON; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MULTIPROTEIN COMPLEXES; PROSTATIC NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84893173665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080300     Document Type: Article

References (42)

1. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149: 274-293. doi:10.1016/j.cell.2012.03.017. PubMed: 22500797.
2. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35. doi:10.1038/nrm3025. PubMed: 21157483.
3. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. doi:10.1016/j.ccr.2007.05.008. PubMed: 17613433. (Pubitemid 47001784)
4. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N (2006) mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195-199. doi:10.1038/sj.bjc.6602902. PubMed: 16404421. (Pubitemid 43151534)
5. Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23: 744-755. doi:10.1016/j.ceb.2011.09.003. PubMed: 21963299.
6. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468. doi: 10.1016/S1097-2765(02)00636- 6. PubMed: 12408816. (Pubitemid 35284167)
7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302. doi:10.1016/j.cub.2004.06.054. PubMed: 15268862. (Pubitemid 38991819)
8. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25: 6416-6422. doi: 10.1038/sj.onc.1209888. PubMed: 17041626. (Pubitemid 44582285)
9. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945. doi:10.1101/gad.1212704. PubMed: 15314020. (Pubitemid 39071573)
10. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470. (Pubitemid 40262113)
11. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871. doi:10.1016/j.devcel.2006.10.007. PubMed: 17141160. (Pubitemid 44804279)
12. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A et al. (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27: 1932-1943. doi:10.1038/emboj.2008.120. PubMed: 18566586.
13. Pópulo H, Lopes JM, Soares P (2012) The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci 13: 1886-1918. doi:10.3390/ijms13021886. PubMed: 22408430.
14. Oh WJ, Jacinto E (2011) mTOR complex 2 signaling and functions. Cell Cycle 10: 2305-2316. doi:10.4161/cc.10.14.16586. PubMed: 21670596.
15. Masri J, Bernath A, Martin J, Jo OD, Vartanian R et al. (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67: 11712-11720. doi: 10.1158/0008-5472. CAN-07-2223. PubMed: 18089801.
16. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159. doi:10.1016/j.ccr.2008.12.017. PubMed: 19185849.
17. Zinzalla V, Stracka D, Oppliger W, Hall MN (2011) Activation of mTORC2 by association with the ribosome. Cell 144: 757-768. doi: 10.1016/j.cell.2011.02. 014. PubMed: 21376236.
18. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. doi:10.1038/nrc1997. PubMed: 17060945. (Pubitemid 44629897)
19. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269. doi:10.1038/nrc1840. PubMed: 16557279.
20. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA et al. (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70: 5184-5193. doi:10.1158/1538-7445. AM10-5184. PubMed: 20501828.
21. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J et al. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70: 4666-4675. doi:10.1158/1538-7445.AM10-4666. PubMed: 20484036.
22. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH et al. (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24: 447-463. doi:10.1210/me.2009-0295. PubMed: 20081105.
23. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A et al. (2011) miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 71: 6450-6462. doi:10.1158/0008-5472.CAN-11-0364. PubMed: 21868754.
24. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K et al. (2011) The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71: 5765-5778. doi:10.1158/0008- 5472.CAN-11-0368. PubMed: 21795477.
25. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214. doi:10.1016/j.ccr.2004.09.001. PubMed: 15380511. (Pubitemid 39222033)
26. Frame MC (2004) Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117: 989-998. doi:10.1242/jcs.01111. PubMed: 14996930.
27. Oneyama C, Hikita T, Nada S, Okada M (2008) Functional dissection of transformation by c-Src and v-Src. Genes Cells 13: 1-12. PubMed: 18173743.
28. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480. doi:10.1038/nrc1366. PubMed: 15170449.
29. Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K et al. (2008) The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 30: 426-436. doi:10.1016/j.molcel.2008.03.026. PubMed: 18498747. (Pubitemid 351672379)
30. Ingley E (2008) Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784: 56-65. doi:10.1016/j.bbapap.2007.08.012. PubMed: 17905674.
31. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H (1991) CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J Biol Chem 266: 24249-24252. PubMed: 1722201. (Pubitemid 21908933)
32. Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T et al. (2011) MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30: 3489-3501. doi:10.1038/onc.2011.63. PubMed: 21383697.
33. Penuel E, Martin GS (1999) Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol Cell Biol 10: 1693-1703. doi:10.1091/mbc.10.6.1693. PubMed: 10359590. (Pubitemid 29272625)
34. Vojtechová M, Turecková J, Kucerová D, Sloncová E, Vachtenheim J et al. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10: 99-107. doi: 10.1593/neo.07905. PubMed: 18283331. (Pubitemid 351240875)
35. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N et al. (2010) Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 24: 460-466. doi:10.1038/leu.2009.246. PubMed: 19956200.
36. Sarkar S, Dey BK, Dutta A (2010) MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Cell Biol 21: 2138-2149. doi:10.1091/mbc.E10-01- 0062. PubMed: 20462953.
37. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X et al. (2013) An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 19: 74-82. PubMed: 23263626.
38. Oneyama C, Morii E, Okuzaki D, Takahashi Y, Ikeda J et al. (2012) MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene 31: 1623-1635. doi:10.1038/onc.2011.367. PubMed: 21860426.
39. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M et al. (2008) Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68: 1618-1624. doi:10.1158/0008-5472.CAN-07-5869. PubMed: 18339839. (Pubitemid 351416544)
40. Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693-702. doi:10.1016/0092-8674(91)90499-O. PubMed: 1997203. (Pubitemid 121001157)
41. Yagi R, Waguri S, Sumikawa Y, Nada S, Oneyama C et al. (2007) Cterminal Src kinase controls development and maintenance of mouse squamous epithelia. EMBO J 26: 1234-1244. doi:10.1038/sj.emboj.7601595. PubMed: 17304209. (Pubitemid 46398715)
42. Schalm SS, Fingar DC, Sabatini DM, Blenis J (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13: 797-806. doi:10.1016/S0960-9822(03)00329-4. PubMed: 12747827. (Pubitemid 36573247)